Page 1

Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2021 Results Foundry revenue of $ 34.7 million in Q3 and $ 78.8 million year - to - date , with strong growth driven by both continued execution and realization of downstream value share 8 products have been manufactured at scale from Ginkgo programs ; number has more than doubled in year - to - date 2021 Biosecurity revenue of $ 42.9 million in Q3 and $ 86.5 million year - to - date has already exceeded full year outlook BOSTON , MA - November 15 , 2021 - Ginkgo Bioworks Holdings , Inc. ( NYSE : DNA ) , the leading horizontal platform for cell programming , today announced its results for the third quarter ended September 30 , 2021. Please visit investors.ginkgobioworks.com to view the update including a slide presentation with additional details on the third quarter and supplemental financial information , which will be posted following the call . " We executed well in the third quarter during an especially exciting time for the company , with our public debut happening in mid - September , " said Jason Kelly , co - founder and Chief Executive Officer . " I am so proud of the team for their relentless effort and continued commitment to our partners , which has resulted in a terrific quarter , with strong growth in both Foundry revenue and our biosecurity offering , Concentric by Ginkgo . I'm particularly excited that this quarter included a realization of downstream value share from Cronos ' commercial scale production of CBG , demonstrating the potential for this component of our business model . " Recent Business Highlights • Listed on the New York Stock Exchange under ticker “ DNA " after closing a business combination that provided Ginkgo with gross proceeds of over $ 1.6 billion Added 10 new programs in Q3 ( bringing the year - to - date total to 21 ) , with 61 total active programs during the first three quarters of 2021 Existing program and partner milestones included : the public announcement of a $ 78 million Series A fundraise by Arcaea ( formerly known as Kalo Ingredients ) , including Chanel and Givaudan as strategic investors ; the announcement of Motif FoodWorks ' first two products ( HEMAMI ™ and APPETEX ™ ) ; the commencement of commercial operations by Aldevron for vaccinia capping enzyme , which they are producing using a Ginkgo - engineered strain that improved efficiency by over 10x ; the achievement of our first equity milestone for Cronos in Q3 , demonstrating full target performance for manufacturing of CBG and the first commercial launch of products containing biosynthetic CBG in October . Additionally , we're thrilled to announce that just last week , Cronos successfully validated full target performance for a second cannabinoid molecule , CBGV , unlocking a second equity milestone ( which will be recorded in our Q4 financials ) ;